Small prospective nonrandomized trial with 41 patients, 21 treated with curcumin, showing lower disease progression and faster recovery with treatment. IRCT20200408046990N1.
Saber-Moghaddam et al., 1/3/2021, prospective, Iran, Middle East, peer-reviewed, 9 authors.
risk of disease progression, 94.3% lower, RR 0.06, p = 0.001, treatment 0 of 21 (0.0%), control 8 of 20 (40.0%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of no recovery, 38.4% lower, RR 0.62, p = 0.04, treatment 11 of 21 (52.4%), control 17 of 20 (85.0%).
hospitalization time, 44.8% lower, relative time 0.55, p < 0.001, treatment 21, control 20.
Effect extraction follows pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.